Intravenous Vitamin C and Cancer: Evidence and Uncertainties

Can very high doses of vitamin C help treat cancer?

Researchers have investigated this possibility for decades. Although vitamin C is usually thought of as an antioxidant, at very high concentrations it may behave differently and potentially damage cancer cells.

Recent clinical trials, particularly involving pancreatic cancer, have produced some encouraging results.

However, high-dose intravenous vitamin C remains an experimental cancer treatment. It has not been established as effective against cancer.

Why Intravenous Rather Than Oral Vitamin C?

Vitamin C is an essential nutrient found in fruits, vegetables, and supplements.

When taken orally, the body limits how much vitamin C enters the bloodstream.

Intravenous administration bypasses the digestive system and can produce blood concentrations many times higher than those achieved with supplements.

At these concentrations, vitamin C may promote the formation of hydrogen peroxide outside cells. Laboratory experiments suggest that this can damage certain cancer cells.

Researchers are investigating whether these effects can improve cancer treatment without causing excessive harm to healthy tissues.

The important distinction is that the potential anticancer effects being studied require concentrations that oral supplements cannot ordinarily achieve.

The History: Linus Pauling and Vitamin C

Interest in vitamin C as a cancer treatment dates back more than 50 years.

Linus Pauling, a two-time Nobel Prize winner, and Scottish physician Ewan Cameron reported encouraging results using vitamin C in patients with advanced cancer.

However, subsequent randomized studies at the Mayo Clinic failed to demonstrate a survival benefit.

For many years, these negative findings discouraged further investigation.

An important difference later emerged: the Mayo Clinic trials used oral vitamin C, while Cameron and Pauling had used regimens that included intravenous administration.

Researchers subsequently demonstrated that intravenous administration could achieve substantially higher blood concentrations.

This renewed scientific interest, although it did not establish that Pauling's original claims were correct.

Pancreatic Cancer: An Encouraging Clinical Trial

One of the most promising studies was published in 2024 by researchers at the University of Iowa.

The randomized trial involved 36 patients with metastatic pancreatic cancer, of whom 34 received their assigned treatment.

Patients received either standard chemotherapy or the same chemotherapy combined with high-dose intravenous vitamin C.

The vitamin C group received 75 grams intravenously three times weekly.

What Were the Results?

Median overall survival:

Chemotherapy alone: 8.3 months
Chemotherapy plus vitamin C: 16 months

Median time before cancer progression:

Chemotherapy alone: 3.9 months
Chemotherapy plus vitamin C: 6.2 months

Researchers also reported that adding vitamin C did not increase the overall frequency or severity of adverse events.

The survival difference is substantial and deserves attention.

However, the study was small, and its findings need confirmation in larger trials involving more patients and different treatment centers.

The results are encouraging but do not establish that intravenous vitamin C prolongs survival in pancreatic cancer generally.

A Second Pancreatic Cancer Trial

A study published in 2025 investigated intravenous vitamin C combined with three chemotherapy drugs.

Seventeen patients with metastatic pancreatic cancer participated.

Median overall survival was 14.2 months, and median progression-free survival was 7.1 months.

However, the researchers did not find evidence of improved cancer response compared with historical results for chemotherapy alone.

This study was designed primarily to evaluate safety and dosing, rather than prove effectiveness.

Together, these studies illustrate why additional research is necessary.

See: New Developments in Pancreatic Cancer Treatment →

What About Breast Cancer?

Intravenous vitamin C has also been investigated in breast cancer.

Some studies have reported improvements in symptoms such as fatigue, nausea, pain, and appetite loss among patients receiving conventional cancer treatment.

However, the evidence is limited, and studies have generally been small.

There is not yet convincing clinical evidence that intravenous vitamin C reduces breast cancer recurrence or extends survival.

Researchers continue to investigate whether it may improve treatment tolerance or enhance the effects of chemotherapy.

See: Diet, Exercise & Metabolic Health in Breast Cancer

Other Cancers

Researchers have investigated intravenous vitamin C in several other cancers, including ovarian cancer, lung cancer, colorectal cancer, and brain tumors.

Some early studies have reported reduced treatment-related side effects or encouraging survival findings.

Others have found little or no benefit.

Results from one cancer cannot automatically be applied to another because cancers differ substantially in their biology and response to treatment.

What Do Case Studies Tell Us?

Some of the renewed interest in intravenous vitamin C comes from published reports of patients with advanced cancer who experienced unexpectedly favorable outcomes.

In 2006, researchers published three carefully documented cases involving kidney cancer, bladder cancer, and lymphoma.

The patients had received intravenous vitamin C and experienced unusually favorable disease courses.

Other published reports have described patients with pancreatic cancer, breast cancer, and additional cancers.

These reports are worth investigating because they may help researchers identify treatments deserving formal clinical trials.

However, individual cases cannot establish that vitamin C caused the improvement.

Some patients also received conventional treatments, and unusual outcomes occasionally occur without experimental therapy.

Case studies can generate useful scientific questions, but randomized trials are needed to determine whether a treatment works.

Is High-Dose Intravenous Vitamin C Safe?

Intravenous vitamin C has generally been well tolerated in appropriately screened patients participating in clinical trials.

However, high doses can cause serious problems in certain individuals.

Important concerns include:

Kidney disease: High doses may increase the risk of kidney injury.
Kidney stones: People with a history of certain kidney stones may be at increased risk.
G6PD deficiency: An inherited enzyme deficiency that can lead to destruction of red blood cells following high-dose vitamin C.
Iron overload: Vitamin C may be inappropriate for people with hemochromatosis.
Blood glucose testing: High concentrations can interfere with some glucose monitoring devices.
Cancer treatments: Possible interactions depend on the drugs being used.

Patients should discuss intravenous vitamin C with their oncologist before considering treatment.

What Does Intravenous Vitamin C Cost?

High-dose intravenous vitamin C can be expensive, particularly when treatments are given several times weekly.

Costs vary considerably by provider, dose, and location. Individual infusions may cost approximately $150–$500 or more, potentially adding up to thousands of dollars over several months.

Because intravenous vitamin C is not an established cancer treatment, Medicare and most private insurers generally do not cover it when used specifically to treat cancer outside a clinical trial.

Patients considering treatment should ask about the total cost, including medical evaluations, laboratory testing, and repeated infusions.

Participation in a clinical trial may provide access to the investigational treatment without paying for the drug itself, although other expenses may remain.

What About Older Adults?

Cancer treatment decisions in people in their 70s and 80s should consider kidney function, other medical conditions, medications, and overall physical health.

Older adults are often underrepresented in clinical trials.

For example, the 2025 pancreatic cancer study had a median participant age of approximately 64.

Patients considering intravenous vitamin C should ask whether the treatment has been studied in people of similar age and health.

The need for repeated infusions, sometimes several times weekly, is another practical consideration.

What Is the Current Medical Position?

The National Cancer Institute has reviewed the research on intravenous vitamin C, including laboratory experiments, clinical trials, and patient outcomes.

Some studies have reported improvements in symptoms, treatment tolerance, or survival.

However, the evidence remains insufficient to establish intravenous vitamin C as an effective cancer treatment.

The FDA has not approved intravenous vitamin C for treating cancer.

Clinical trials remain the best way to determine whether it offers meaningful benefits.

The Important Point

High-dose intravenous vitamin C is an intriguing area of cancer research, particularly because of the encouraging 2024 pancreatic cancer trial.

Unlike many alternative cancer treatments, it has been investigated in randomized clinical trials, and researchers have proposed plausible biological mechanisms.

Nevertheless, the evidence remains preliminary.

For patients interested in this approach, participation in a properly designed clinical trial is preferable to receiving unproven treatment outside established cancer care.

Intravenous vitamin C should not replace conventional cancer treatment.

Where Can Patients Find Knowledgeable Doctors?

Patients interested in high-dose intravenous vitamin C should look for oncologists familiar with clinical research involving this treatment.

National Cancer Institute — Find a Cancer Center

NCI-designated cancer centers can help patients locate specialists and clinical trials.

ClinicalTrials.gov — Intravenous Vitamin C and Cancer

Find clinical trials, participating institutions, and research contacts.

Some integrative medicine clinics also offer intravenous vitamin C. Patients should choose physicians who coordinate with their oncologist, perform appropriate safety testing, and explain the costs and limitations of the evidence.

Participation in a clinical trial is preferable whenever possible.